{
  "url": "https://openlegislation.uk/eu-regulation-2009-761/annex-III/division-1/division-1.6/division-1.6.1/division-1.6.1.3",
  "json_url": "https://openlegislation.uk/eu-regulation-2009-761/annex-III/division-1/division-1.6/division-1.6.1/division-1.6.1.3.json",
  "legislation": "eur/2009/761",
  "legislation_title": "Commission Regulation (EC) No 761/2009 of 23 July 2009 amending, for the purpose of its adaptation to technical progress, Regulation (EC) No 440/2008 laying down test methods pursuant to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2009-761",
  "path": "annex/III/division/1/division/1.6/division/1.6.1/division/1.6.1.3",
  "kind": "division",
  "number": "1.6.1.3",
  "heading": "Application of the Test and Control Substances",
  "text": "A sufficient number of tissue replicates should be used for each treatment and for controls (at least three replicates per run). For liquid as well as solid substances, sufficient amount of test substance should be applied to uniformly cover the skin surface while avoiding an infinite dose (see 1.2 Definitions), i.e. a minimum of 25 μL/cm2 or 25 mg/cm2 should be used. For solid substances, the epidermis surface should be moistened with deionised or distilled water before application, to ensure good contact with the skin. Whenever possible, solids should be tested as a fine powder. At the end of the exposure period, the test substance should be carefully washed from the skin surface with aqueous buffer, or 0,9 % NaCl. Depending on the reconstructed human epidermis model used, the exposure period may vary between 15 to 60 minutes, and the incubation temperature between 20 and 37 °C. For details, see the Standard Operating Procedures for the three methods (21, 22, 23).\nConcurrent NC and positive controls (PC) should be used for each study to demonstrate that viability (NC), barrier function and resulting tissue sensitivity (PC) of the tissues are within a defined historical acceptance range. The suggested PC substance is 5 % aqueous SDS. The suggested NC substances are water or phosphate buffered saline (PBS).",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2009/761/annex/III/division/1/division/1.6/division/1.6.1/division/1.6.1.3",
    "retrieved_at": "2026-11-01T14:51:19.625001+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}